Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients - Trial NCT06408935
Access comprehensive clinical trial information for NCT06408935 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen-Cilag Ltd. and is currently Recruiting. The study focuses on Crohn's Disease. Target enrollment is 112 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Janssen-Cilag Ltd.
Timeline & Enrollment
Phase 3
Apr 17, 2024
Aug 30, 2028
Primary Outcome
Percentage of Participants Achieving a Magnetic Resonance Index of Activity (MaRIA) Less Than ()11 in All Intestinal Segments at Week 48
Summary
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers
 of the digestive tract (transmural healing) with the help of a score called Magnetic
 Resonance Index of Activity (MaRIA) based on a scan at Week 48.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06408935
Non-Device Trial